JP2020002094A - 血中酸素濃度低下抑制剤 - Google Patents
血中酸素濃度低下抑制剤 Download PDFInfo
- Publication number
- JP2020002094A JP2020002094A JP2018124672A JP2018124672A JP2020002094A JP 2020002094 A JP2020002094 A JP 2020002094A JP 2018124672 A JP2018124672 A JP 2018124672A JP 2018124672 A JP2018124672 A JP 2018124672A JP 2020002094 A JP2020002094 A JP 2020002094A
- Authority
- JP
- Japan
- Prior art keywords
- blood oxygen
- oxygen concentration
- agent
- formula
- decrease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Ge−(CH2−CH2−COOH)2O3
で表される有機ゲルマニウム化合物を有効成分とすることを特徴とするものである。
Ge−(CH2−CH2−COOH)2O3
で表される公知のもので、ゲルマニウム原子にプロパン酸の3位の炭素が共有結合しているゲルミルプロピオン酸と酸素原子とが2:3の割合で結合した非常に安定な分子である。
[(Ge−CH2−CH2−COOH)2O3]n
等で表わすこともでき、当該有機ゲルマニウム化合物は、重合度nを用いて表した場合は、重合度n=2〜∞のオリゴマー乃至ポリマー(poly-trans-[(2-carboxyethyl)germasesquioxane])ということができるが、重合度nを用いずに表した場合も化合物としては同一である。
実施例1
実施例2
Claims (2)
- 式[I]
Ge−(CH2−CH2−COOH)2O3
で表される有機ゲルマニウム化合物を有効成分として含有することを特徴とする血中酸素濃度低下抑制剤。 - 式[II]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018124672A JP2020002094A (ja) | 2018-06-29 | 2018-06-29 | 血中酸素濃度低下抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018124672A JP2020002094A (ja) | 2018-06-29 | 2018-06-29 | 血中酸素濃度低下抑制剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020002094A true JP2020002094A (ja) | 2020-01-09 |
Family
ID=69098653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018124672A Pending JP2020002094A (ja) | 2018-06-29 | 2018-06-29 | 血中酸素濃度低下抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2020002094A (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56144025A (en) * | 1980-04-09 | 1981-11-10 | Asai Germanium Res Inst | Prevention of oxygen defficient death of fishes and shellfishes |
JP2001316257A (ja) * | 2000-05-09 | 2001-11-13 | Asai Germanium Research Inst | 赤血球の変形能改善剤 |
-
2018
- 2018-06-29 JP JP2018124672A patent/JP2020002094A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56144025A (en) * | 1980-04-09 | 1981-11-10 | Asai Germanium Res Inst | Prevention of oxygen defficient death of fishes and shellfishes |
JP2001316257A (ja) * | 2000-05-09 | 2001-11-13 | Asai Germanium Research Inst | 赤血球の変形能改善剤 |
Non-Patent Citations (1)
Title |
---|
日本バイオレオロジー学会誌, vol. 6(1), JPN6022007118, 1992, pages 2 - 16, ISSN: 0004715626 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Neuman et al. | Prevention of exercise-induced asthma by a natural isomer mixture of β-carotene | |
Pavord et al. | Inhaled frusemide and exercise induced asthma: evidence of a role for inhibitory prostanoids. | |
BR112018000592B1 (pt) | Composição de desbloqueio de nariz congestionado tendo atividade antiviral | |
JPWO2019044964A1 (ja) | ケンペロール類縁体含有組成物 | |
BR112013011259B1 (pt) | Uso de 25-hidroxivitamina D3 para a fabricação de um produto farmacêutico, alimento, ou nutracêutico para manter níveis saudáveis de eotaxina | |
Wilkens et al. | Effects of a PAF‐antagonist (BN 52063) on bronchoconstriction and platelet activation during exercise induced asthma. | |
EP2477642A1 (en) | Method of treating asthma with antiviral agents | |
Hofmeyr et al. | Acute high-altitude illness | |
JP2020002094A (ja) | 血中酸素濃度低下抑制剤 | |
US7645795B2 (en) | Method for treating amyotrophic lateral sclerosis | |
JP6852920B2 (ja) | 動脈血中酸素飽和度の向上剤 | |
JP5916717B2 (ja) | 高地低酸素症の処置 | |
US11844811B2 (en) | Methods and compositions for alleviating respiratory dysfunction | |
US20180153824A1 (en) | Treatment of acute complications of sickle cell disease | |
JP2022033333A (ja) | 心血管代謝疾患の治療剤または予防剤 | |
Connett et al. | Prolonged hypoxaemia after nebulised salbutamol. | |
ES2856553T3 (es) | Composiciones que comprenden dihidroquercetina para uso en métodos para el tratamiento del herpes | |
US8927600B2 (en) | Compound for use in the treatment of peripheral neuropathies | |
JP5734134B2 (ja) | 抗疲労用医薬組成物 | |
US20230116276A1 (en) | Dietary supplement comprising aldehyde functional monoterpenoids | |
TW201731497A (zh) | 一種苯酞類化合物用於製備預防癌症之醫藥組合物的用途 | |
JP4896531B2 (ja) | 血中CoQ10量を増加させる医薬組成物 | |
JPS63503068A (ja) | 抗風邪キット、抗風邪製剤およびそれらの使用 | |
KOSYKH | CLINICAL MANAGEMENT AND TREATMENT OF PATIENTS WITH COVID-19 INFECTION | |
JP2023125423A (ja) | 運動時の脂質代謝促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180629 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210507 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220301 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220906 |